BA
Bandhan Healthcare Fund Direct Growth
Latest NAV
+0.00% 1Y
Sign In to Add to Portfolio
Benchmark: BSE Healthcare TRI
Expense ratio
1.22%
AUM
₹332 Cr
Min SIP
₹100
Min lump sum
₹1,000
1Y
+0.00%
3Y (ann.)
+0.00%
5Y (ann.)
+0.00%
Launched
Nov 2025
Where the NAV sits & how risky it is
₹11.07
52-week range
at 80%
₹11.07
Low 29 Jan 2026₹9.10
High 31 Aug 2026₹11.58
Risk level
Very High
Low
Very high
NAV history
02 Dec 2025
Since inception
01 Oct 2026
Returns by period
1W
-3.65%
1M
-3.29%
3M
+2.81%
6M
+19.95%
1Y
+0.00%
3Y
+0.00%
5Y
+0.00%
3Y and 5Y returns are annualised.
Return calculator
You invest
—
Est. gain
—
Est. value
—
Invested Gain
Invested
Projected value
min SIP ₹100
Estimate only. It assumes the selected past return repeats every year; 3Y and 5Y figures are taken as annualised. This scheme is too new to have a track record for any of those windows, so the calculator starts on a neutral custom rate — change it to whatever you assume.
Where your money goes
AS OF 31 MAY 2026
Equity 96.27%
Cash & other 4.33%
Sector split
Country split
Top 5 hold 36.8%
Top 10 hold 55.9%
40 equity holdings
Equity holdings
(top 30)
| # | Holding | Sector | Country | Weight | YTD |
|---|---|---|---|---|---|
| 1 | Sun Pharmaceutical
INE044A01036 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
8.68%
|
+5.35% |
| 2 | Apollo Hospitals
INE437A01024 |
Healthcare Medical Care Facilities |
India |
8.68%
|
+19.28% |
| 3 | Cipla
INE059A01026 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
6.76%
|
-8.28% |
| 4 | Divis Laboratories
INE361B01024 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
6.43%
|
+5.01% |
| 5 | Max Healthcare Institute
INE027H01010 |
Healthcare Medical Care Facilities |
India |
6.29%
|
-2.01% |
| 6 | Dr Reddys Laboratories
INE089A01031 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
5.03%
|
+0.43% |
| 7 | J B Chemicals and Pharmaceuticals
INE572A01036 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
4.53%
|
+21.71% |
| 8 | Glenmark Pharmaceuticals
INE935A01035 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
3.66%
|
+5.97% |
| 9 | Dr. Lal Path Labs
INE600L01024 |
Healthcare Diagnostics & Research |
India |
3.00%
|
+10.99% |
| 10 | Ajanta Pharma
INE031B01049 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
2.83%
|
+11.22% |
About this scheme
The scheme seeks to generate long-term capital appreciation by investing predominantly in equity and equity-related instruments of companies engaged in Healthcare, Pharma and Allied sectors. Disclaimer: There is no assurance or guarantee that the scheme’s objectives will be realised.
Fund manager(s): Viraj Kulkarni,Brijesh Shah,Ritika Behera,Gaurav Satra
Exit load: Exit load of 0.50%, if redeemed within 30 days.
Scheme snapshot
VR Rating
MS Rating
Plan
Growth
Type
DIRECT
Inception
28 Nov 2025
Lump-sum min
₹1,000
SIP
Purchase
Switch
STP
SWP
Similar schemes
RANKED BY 1Y RETURN
Nippon India Taiwan Equity Fund Direct Growth
1▲ 121.5 pts ahead of this fund
Franklin Asian Equity Fund Direct Growth
2▲ 33.4 pts ahead of this fund
Nippon India Japan Equity Fund - Direct Plan - Growth Plan - Bonus Option
3▲ 30.6 pts ahead of this fund
Nippon India Japan Equity Fund Direct Growth
4▲ 30.6 pts ahead of this fund
Bank of India Small Cap Fund Direct Growth
5▲ 29.2 pts ahead of this fund
TRUSTMF Small Cap Fund Direct Growth
6▲ 29.1 pts ahead of this fund